LBP
Reaktivität: Human
WB, IHC (p)
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
ELISA, LBP inhibition studies, Western Blot. Non inhibition of LPS binding to membrane bound CD14, Binding titre at - ELISA: more than1:20.000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Reconstitute with bidistilled water
Konzentration
1 mg/mL
Buffer
PBS, pH 7.18
Konservierungsmittel
Without preservative
Lagerung
-20 °C,-80 °C
Stamme, Mueller, Hamann, Gutsmann, Seydel: "Surfactant protein a inhibits lipopolysaccharide-induced immune cell activation by preventing the interaction of lipopolysaccharide with lipopolysaccharide-binding protein." in: American journal of respiratory cell and molecular biology, Vol. 27, Issue 3, pp. 353-60, (2002) (PubMed).
Gutsmann, Mueller, Carroll, MacKenzie, Wiese, Seydel: "Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells." in: Infection and immunity, Vol. 69, Issue 11, pp. 6942-50, (2001) (PubMed).
Hamann, Schumann, Flad, Brade, Rietschel, Ulmer: "Binding of lipopolysaccharide (LPS) to CHO cells does not correlate with LPS-induced NF-kappaB activation." in: European journal of immunology, Vol. 30, Issue 1, pp. 211-6, (2000) (PubMed).
Target
LBP
(Lipopolysaccharide Binding Protein (LBP))
Andere Bezeichnung
Lipopolysaccharide (LPS)-Binding Protein (LBP) (LBP Produkte)
Background: Natural Lipopolysccaride Binding Protein (LBP) is a 58KD glycoprotein produced in liver. It binds at lipid A of LPS with high affinity (10-9M) and reduced the cellular LPS effects at CD14+ cells (IL1ß, IL6, TNFα). It acts as opsonin for GRAM negative cells, LPS, neutrophiles and granulocytes.